FABP4 has been proposed as a therapeutic target, and FABP4 elevation in primary ovarian cancer tissue was significantly associated with the risk of residual disease after primary debulking surgery in patients with high-grade serous carcinoma [47]. This evidence concerns the gene FABP4 and serous adenocarcinoma.